Cargando…
Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review
IMPORTANCE: Phase 3 trials for patients with metastatic colorectal cancer (mCRC) have been conducted with varying designs and often with surrogate end points for overall survival (OS). OBJECTIVES: To critically examine the factors associated with clinically relevant improvement in OS (defined as ≥2...
Autores principales: | Shen, Chan, Tannenbaum, Daniel, Horn, Robert, Rogers, Jane, Eng, Cathy, Zhou, Shouhao, Johnson, Benny, Kopetz, Scott, Morris, Van, Overman, Michael, Parseghian, Christine, Chang, George J., Lopez-Olivo, Maria A., Kanwal, Raghav, Ellis, Lee M., Dasari, Arvind |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131746/ https://www.ncbi.nlm.nih.gov/pubmed/35608860 http://dx.doi.org/10.1001/jamanetworkopen.2022.13588 |
Ejemplares similares
-
Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
por: Serpas Higbie, Victoria, et al.
Publicado: (2022) -
Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
por: Parseghian, Christine, et al.
Publicado: (2023) -
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
por: Johnson, Benny, et al.
Publicado: (2022) -
FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma
por: Korphaisarn, Krittiya, et al.
Publicado: (2017) -
Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma
por: Korphaisarn, Krittiya, et al.
Publicado: (2019)